No cure, no fee? Outcome-based agreements for gene therapies
The significant price-tags associated with gene therapies are leading to questions being raised about value for both patients and payers...
Senior economist, Office of Health Economics
Nadine Henderson is a senior economist at the Office of Health Economics, London, whose research interests centre on issues around the methodology and process of Health Technology Assessment. She has evaluated the appropriateness of Health Technology Assessment methods to assess orphan and ultra-orphan medicines, gene therapies, and tumour-agnostic therapies.
by Nadine Henderson and 1 others
The significant price-tags associated with gene therapies are leading to questions being raised about value for both patients and payers...
Subscribe for free to what PET does best – informing you of the latest in fertility, genomics and embryo research.